Journal article
Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
Abstract
OBJECTIVES: To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children in everyday practice.
METHODS: High-risk children prophylaxed against RSV infection were recruited into a prospective, observational, Canadian RSV Evaluation Study of Palivizumab (CARESS) registry with active, serious adverse event (SAE) monitoring from 2008 to 2013. SAE reports were systematically collected and assessed for severity and …
Authors
Chen JJ; Chan P; Paes B; Mitchell I; Li A; Lanctôt KL; investigators C
Journal
PLOS ONE, Vol. 10, No. 8,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pone.0134711
ISSN
1932-6203